Clotting factor concentrates (CFC) or bypassing agents (BPA)

Phase 3

Sanofi (SNY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

SNYPhase 3$50.8B

Clotting factor concentrates (CFC) or bypassing agents (BPA) Phase 3 Est. Readout

Clotting factor concentrates (CFC) or bypassing agents (BPA)• Hemophilia91

Q2 2027~QConfirmedSTALE

CT.gov

00%

Q1 '27

SNYPhase 3$50.8B

Fitusiran Phase 3 Est. Readout

Clotting factor concentrates (CFC) or bypassing agents (BPA)• Hemophilia91

Q1 2027~QConfirmedSTALE

CT.gov

00%

Competitive Landscape

2 competitors in Hemophilia

View Full Landscape

Drug Information

Target Indication

Hemophilia

Clinical Trial

NCT05662319

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

Fexofenadine, Comparator = MontelukastPhase 3

Asthma

Teriflunomide 14 MG Oral Tablet [Aubagio]Phase 3

Multiple Sclerosis

Dupilumab/DupixentPhase 3

Asthma

dronedaronePhase 3

Atrial Fibrillation

AvidinPhase 3

Embolism

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts